Daqing Wang from 14 Liberty Ln, North Reading, MA 01864, age 65, Phone: (617)2819723

Vehicle Records

Daqing Wang
view source
Address:

14 Liberty Ln, North Reading, MA 01864
VIN:

2HKYF18537H526224
Make:

HONDA
Model:

PILOT
Year:

2007

Resumes

Service

view source

Industry:

Food Production

Work:

Service

Daqing Wang Bedford, MA

view source

Work:

Idera Pharmaceuticals

2002 to 2000
Principal scientist Zycos Inc
Lexington, MA
2000 to 2002
Senior scientist Pharmacy and Pharmaceutical Science
Edmonton, AB
1997 to 2000
Postdoctoral Fellow, Faculty

Education:

Osaka University
1990
Ph.D. in Research Institute for Microbial Disease Zunyi Medical School
Zunyi, CN
1985
M.S. Zunyi Medical School
Zunyi, CN
1982
Bachelor of Medicine

Us Patents

Synergistic Treatment Of Cancer Using Immunomers In Conjunction With Chemotherapeutic Agents
view source
US Patent:

7875594, Jan 25, 2011
Filed:

Jan 28, 2008
Appl. No.:

12/020694
Inventors:

Ekambar R. Kandimalla - Southboro MA, US
Sudhir Agrawal - Shrewsbury MA, US
Daqing Wang - Bedford MA, US
Lakshmi Bhagat - Framingham MA, US
Dong Yu - Westboro MA, US
Assignee:

Idera Pharmaceuticals, Inc. - Cambridge MA
International Classification:

A61K 39/395
US Classification:

514 44
Abstract:

The invention relates to the therapeutic use of immunostimulatory oligonucleotides and/or immunomers in combination with chemotherapeutic agents to provide a synergistic therapeutic effect.

Synthetic Agonists Of Tlr9
view source
US Patent:

7884197, Feb 8, 2011
Filed:

Dec 12, 2007
Appl. No.:

11/954726
Inventors:

Ekambar Kandimalla - Southboro MA, US
Mallikarjuna Putta - Burlington MA, US
Dong Yu - Westboro MA, US
Lakshmi Bhagat - Framingham MA, US
Daqing Wang - Bedford MA, US
Sudhir Agrawal - Shrewsbury MA, US
Assignee:

Idera Pharmaceuticals, Inc. - Cambridge MA
International Classification:

C07H 21/02
C07H 21/04
C12Q 1/68
C12N 5/00
C12N 5/02
A61K 49/00
A61K 31/70
A01N 43/04
US Classification:

536 231, 435 6, 435375, 424 92, 514 44 R
Abstract:

The invention provides novel oligonucleotide-based compounds that individually provide distinct immune response profiles through their interactions as agonists with TLR9. The TLR9 agonists according to the invention are characterized by specific and unique chemical modifications, which provide their distinctive immune response activation profiles.

Synthetic Agonists Of Tlr9
view source
US Patent:

7960362, Jun 14, 2011
Filed:

Jul 31, 2008
Appl. No.:

12/183439
Inventors:

Ekambar Kandimalla - Southboro MA, US
Mallikarjuna Putta - Burlington MA, US
Daqing Wang - Bedford MA, US
Dong Yu - Westboro MA, US
Lakshmi Bhagat - Framingham MA, US
Sudhir Agrawal - Shrewsbury MA, US
Assignee:

Idera Pharmaceuticals, Inc. - Cambridge MA
International Classification:

A01N 43/04
A61K 39/00
A61K 45/00
C07H 21/02
US Classification:

514 44, 4241841, 4242781, 514 11, 536 231
Abstract:

The invention relates to synthetic chemical compositions that are useful for modulation of Toll-Like Receptor (TLR)-mediated immune responses. In particular, the invention relates to agonists of Toll-Like Receptor 9 (TLR9) that generate unique cytokine and chemokine profiles.

Stabilized Immune Modulatory Rna (Simra) Compounds For Tlr7 And Tlr8
view source
US Patent:

8106173, Jan 31, 2012
Filed:

Apr 6, 2007
Appl. No.:

11/697422
Inventors:

Ekambar R. Kandimalla - Southboro MA, US
Tao Lan - Arlington MA, US
Yukui Li - Newton MA, US
Dong Yu - Westboro MA, US
Daqing Wang - Bedford MA, US
Mallikarjuna Reddy Putta - Burlington MA, US
Sudhir Agrawal - Shrewsbury MA, US
Assignee:

Idera Pharmaceuticals, Inc. - Cambridge MA
International Classification:

C07H 21/02
A61K 48/00
US Classification:

536 231, 514 44 R
Abstract:

The invention relates to the therapeutic use of stabilized oligoribonucleotides as immune modulatory agents for immune therapy applications. Specifically, the invention provides RNA based oligoribonucleotides with improved nuclease and RNase stability and that have immune modulatory activity through TLR7 and/or TLR8.

Modulation Of Toll-Like Receptor 3 Expression By Antisense Oligonucleotides
view source
US Patent:

8153605, Apr 10, 2012
Filed:

Aug 4, 2009
Appl. No.:

12/534911
Inventors:

Ekambar Kandimalla - Southboro MA, US
Mallikarjuna Putta - Burlington MA, US
Lakshmi Bhagat - Framingham MA, US
Daqing Wang - Bedford MA, US
Dong Yu - Westboro MA, US
Sudhir Agrawal - Shrewsbury MA, US
Assignee:

Idera Pharmaceuticals, Inc. - Cambridge MA
International Classification:

C12N 15/11
C12Q 1/68
C07H 21/04
US Classification:

514 44A, 435 61, 536 231, 536 245
Abstract:

Antisense oligonucleotide compounds, compositions and methods are provided for down regulating the expression of TLR3. The compositions comprise antisense oligonucleotides targeted to nucleic acids encoding TLR3. The compositions may also comprise antisense oligonucleotides targeted to nucleic acids encoding TLR3 in combination with other therapeutic and/or prophylactic compounds and/or compositions. Methods of using these compounds and compositions for down-regulating TLR3 expression and for prevention or treatment of diseases wherein modulation of TLR3 expression would be beneficial are provided.

Modulation Of Toll-Like Receptor 5 Expression By Antisense Oligonucleotides
view source
US Patent:

8153777, Apr 10, 2012
Filed:

Nov 4, 2009
Appl. No.:

12/612413
Inventors:

Ekambar Kandimalla - Southboro MA, US
Mallikarjuna Putta - Burlington MA, US
Lakshmi Bhagat - Framingham MA, US
Daqing Wang - Bedford MA, US
Dong Yu - Westboro MA, US
Sudhir Agrawal - Shrewsbury MA, US
Assignee:

Idera Pharmaceuticals, Inc. - Cambridge MA
International Classification:

C07H 21/04
C07H 21/02
A61K 48/00
A61K 39/395
C12N 15/63
US Classification:

536 245, 536 231, 536 2431, 536 2433, 514 44, 4241301, 4353201
Abstract:

Antisense oligonucleotide compounds, compositions and methods are provided for down regulating the expression of TLR5. The compositions comprise antisense oligonucleotides targeted to nucleic acids encoding TLR5. The compositions may also comprise antisense oligonucleotides targeted to nucleic acids encoding TLR5 in combination with other therapeutic and/or prophylactic compounds and/or compositions. Methods of using these compounds and compositions for down-regulating TLR5 expression and for prevention or treatment of diseases wherein modulation of TLR5 expression would be beneficial are provided.

Stabilized Immune Modulatory Rna (Simra) Compounds
view source
US Patent:

8188261, May 29, 2012
Filed:

Jul 7, 2008
Appl. No.:

12/168641
Inventors:

Ekambar Kandimalla - Southboro MA, US
Tao Lan - Arlington MA, US
Daqing Wang - Bedford MA, US
Lakshmi Bhagat - Framingham MA, US
Sudhir Agrawal - Shrewsbury MA, US
Assignee:

Idera Pharmaceuticals, Inc. - Cambridge MA
International Classification:

C07H 21/04
US Classification:

536 245, 536 2431, 536 241, 514 44
Abstract:

The invention relates to the therapeutic use of novel stabilized oligoribonucleotides as immune modulatory agents for immune therapy applications. Specifically, the invention provides novel RNA-based oligoribonucleotides with improved nuclease and RNase stability and that have immune modulatory activity through TLR7 and/or TLR8.

Synthetic Rna-Based Agonists Of Tlr7
view source
US Patent:

8202974, Jun 19, 2012
Filed:

Feb 10, 2010
Appl. No.:

12/703612
Inventors:

Tao Lan - Arlington MA, US
Ekambar Kandimalla - Southboro MA, US
Daqing Wang - Bedford MA, US
Sudhir Agrawal - Shrewsbury MA, US
Assignee:

Idera Pharmaceuticals, Inc. - Cambridge MA
International Classification:

C07H 21/02
C07H 21/04
C12Q 1/68
C12N 5/00
C12N 5/02
A61K 49/00
A61K 31/70
A01N 43/04
US Classification:

536 231, 435 61, 435375, 424 92, 514 44 R
Abstract:

The invention relates to the therapeutic use of stabilized oligoribonucleotides as immune modulatory agents for immune therapy applications. Specifically, the invention provides RNA-based oligoribonucleotides with improved nuclease and RNase stability and that selectively induce immune modulatory activity through TLR7.